Amplia Therapeutics Limited (ASX:ATX)
Australia
· Delayed Price · Currency is AUD | Market Cap | 84.66M |
| Revenue (ttm) | 5.01M |
| Net Income (ttm) | -7.93M |
| Shares Out | 513.07M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 478,630 |
| Average Volume | 5,203,538 |
| Open | 0.160 |
| Previous Close | 0.165 |
| Day's Range | 0.155 - 0.162 |
| 52-Week Range | 0.049 - 0.425 |
| Beta | -0.21 |
| RSI | 46.53 |
| Earnings Date | May 29, 2026 |
About Amplia Therapeutics
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed... [Read more]
Financial Performance
In fiscal year 2025, Amplia Therapeutics's revenue was 3.78 million, a decrease of -15.03% compared to the previous year's 4.45 million. Losses were -6.57 million, 45.9% more than in 2024.
Financial StatementsNews
Accent Trial Mature Data Presented at International Conference
HIGHLIGHTS Mature data from Amplia's ACCENT trial in pancreatic cancer is being presented at the prestigious American Association of Cancer Research (AACR) annual meeting The ACCENT trial investigates...
Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC...
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
HIGHLIGHTS Amplia's lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conference Data showing narmafotinib activity in preclinical m...
Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
Melbourne, Australia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Two US-based sites have completed trial initiation activities for the AMPLICITY trial in pancreatic cancer These sites join the two A...
Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to demons...
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer Symposium Updated data analysis continues to show t...
Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
Melbourne, Australia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) (“Amplia” or the “Company”) is pleased to announce that the Company's CMO Dr Jason Lickliter ...
Additional Confirmed Response Reported as Part of Amplia Investor Presentation
HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trial This brings the confirmed Objective Response Rate to 35% Updated data to be presented at the Life Scie...
Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...